Want to see TSE:COV full AI Analyst Report?
Top Page
Covalon Technologies
(COV)
Select Model
Select Model
Rating:65Neutral
Price Target:
C$2.50
▲(42.86% Upside)
Action:Reiterated
Date:05/22/26
The score is driven by solid financial stability (low leverage) and positive cash generation, plus constructive technical uptrend signals. These positives are partially offset by compressed TTM profitability and a steep valuation (very high P/E) with no dividend support.
Positive Factors
Conservative balance sheet / low leverage
Very low debt (debt-to-equity ~0.08 TTM) gives the company durable financial flexibility to fund operations, absorb demand swings, and invest in manufacturing or distribution without relying on external financing. This materially reduces refinancing and solvency risk over the next 2–6 months and supports strategic optionality.
Negative Factors
Compressed gross and net margins
A material decline in gross margin and a much lower net margin narrow the company’s earnings cushion versus cost or pricing shocks. Persistent margin compression can limit reinvestment, reduce returns on new commercial spend, and make profitability fragile until product mix or pricing recovers, posing a multi-month structural headwind.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low debt (debt-to-equity ~0.08 TTM) gives the company durable financial flexibility to fund operations, absorb demand swings, and invest in manufacturing or distribution without relying on external financing. This materially reduces refinancing and solvency risk over the next 2–6 months and supports strategic optionality.
Read all positive factors
Covalon Technologies (COV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$58.00M
Dividend YieldN/A
Average Volume (3M)17.17K
Price to Earnings (P/E)36.0
Beta (1Y)0.31
Revenue Growth-3.44%
EPS Growth-57.64%
CountryCA
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding27,618,076
10 Day Avg. Volume12,083
30 Day Avg. Volume17,167
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)1.87
Price to Sales (P/S)1.75
P/FCF Ratio34.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.90Price Target Upside65.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)C$36.36M
Covalon Technologies Business Overview & Revenue Model
Company Description
Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe,...
How the Company Makes Money
Covalon makes money primarily by selling its medical device products (notably advanced wound care dressings and infection-prevention/protection products for medical devices) to healthcare providers and through distribution channels in its served m...
Covalon Technologies Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong sequential revenue growth, successful international expansion, and a robust cash position, indicating positive forward momentum. However, year-over-year revenue decline and decreased adjusted EBITDA present concerns, although these may be offset by promising innovations and clinical study results.Positive Updates
Sequential Revenue Growth
Revenue at $8.4 million was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in the U.S. advanced wound care sales channel.
Negative Updates
Decline in Year-Over-Year Revenue
Q3 revenue came in 9% below last year's Q3, which was their highest revenue quarter of 2024.
Read all updates
Q3-2025 Updates
Positive
Negative
Sequential Revenue Growth
Revenue at $8.4 million was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in the U.S. advanced wound care sales channel.
Read all positive updates
Company Guidance
During Covalon's Q3 Fiscal 2025 conference call, CEO Brent Ashton provided optimistic guidance, emphasizing key financial and operational metrics. The company reported $8.4 million in revenue for Q3, marking a sequential increase of over 10% from Q2, driven by more than 40% growth in its U.S. advanced wound care sales. Despite a year-over-year revenue decline of 9% for Q3, the company achieved an adjusted EBITDA of nearly $1 million, reflecting a 50% increase from the previous quarter. Ashton highlighted a robust 13% growth in trailing 12-month revenue and a 27% compounded annual growth rate over three years, illustrating Covalon's market success. Additionally, the company maintained a strong cash position of over $18 million, up almost $9 million from the previous year. Operationally, Covalon achieved 100% retention of its top 50 U.S. hospital customers and added 15 new hospital accounts in Q3, with a total of 65 new accounts for the year. Ashton also shared promising updates on the company's innovation pipeline and international market expansion, including new product registrations and distribution agreements.Covalon Technologies Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
80
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Sep 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.68M | 32.82M | 31.17M | 26.60M | 18.15M | 19.56M |
| Gross Profit | 17.31M | 17.47M | 18.93M | 14.36M | 7.49M | 9.70M |
| EBITDA | 2.09M | 3.01M | 3.14M | -3.56M | -8.11M | 1.54M |
| Net Income | 1.64M | 2.06M | 2.67M | -4.46M | -9.66M | 23.48M |
Balance Sheet | ||||||
| Total Assets | 33.18M | 36.12M | 31.81M | 24.90M | 30.38M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 16.57M | 17.37M | 16.75M | 8.79M | 14.06M | 22.95M |
| Total Debt | 1.77M | 2.25M | 901.67K | 1.56M | 2.17M | 2.59M |
| Total Liabilities | 5.16M | 5.40M | 4.30M | 6.11M | 6.15M | 7.21M |
| Stockholders Equity | 28.02M | 30.73M | 27.50M | 18.79M | 24.23M | 33.37M |
Cash Flow | ||||||
| Free Cash Flow | 4.71M | 1.65M | 3.06M | -4.50M | -9.08M | 443.71K |
| Operating Cash Flow | 6.09M | 2.29M | 3.47M | -3.18M | -7.99M | 621.37K |
| Investing Cash Flow | -1.55M | -847.02K | -281.63K | -81.02K | -843.02K | -278.53K |
| Financing Cash Flow | -4.87M | -529.35K | 4.97M | -2.16M | -2.19M | -8.25M |
Covalon Technologies Technical Analysis
Neutral
1.75
Price Trends
2.06
Positive
1.92
Positive
1.91
Positive
Market Momentum
0.03
Positive
45.90
Neutral
49.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:COV, the sentiment is Neutral. The current price of 1.75 is below the 20-day moving average (MA) of 2.17, below the 50-day MA of 2.06, and below the 200-day MA of 1.91, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 49.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:COV.
Covalon Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$58.00M | 36.01 | 3.31% | ― | -3.44% | -57.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$50.98M | -3.85 | ― | ― | ― | 49.13% | |
46 Neutral | C$49.12M | -23.33 | ― | ― | 45.72% | 35.82% | |
41 Neutral | C$30.66M | -1.78 | -103.51% | ― | ― | -42.77% | |
41 Neutral | C$33.35M | -3.94 | ― | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:COV
Covalon Technologies
2.10
-0.18
-7.89%
TSE:MDNA
Medicenna Therapeutics Corp
0.40
-0.48
-54.60%
TSE:MIR
Medmira
0.07
>-0.01
-6.67%
TSE:SVA
Sernova
0.14
>-0.01
-6.90%
TSE:NRX
NurExone Biologic
0.55
-0.16
-22.54%
TSE:DTC
Defence Therapeutics
0.44
-0.29
-39.73%
Covalon Technologies Corporate Events
Business Operations and Strategy
Covalon Builds Momentum in Vascular Access, Infection Prevention and Wound Care
Positive
Apr 15, 2026
Covalon Technologies has reported a series of commercial and market-development milestones that underscore rising demand for its vascular access and infection-prevention solutions. At the recent Infusion Nurses Society Annual Meeting, the company ...
Business Operations and StrategyProduct-Related Announcements
Covalon Highlights Infection Prevention Leadership at Infusion Nurses Society 2026 Meeting
Positive
Apr 10, 2026
Covalon Technologies will showcase its vascular access and infection prevention solutions at the Infusion Nurses Society 2026 Annual Meeting in Louisville, highlighting the growing adoption of its VALGuard Vascular Access Line Guard and CovaClear ...
Business Operations and StrategyExecutive/Board Changes
Covalon Grants Deferred Share Units to Directors Under Updated Incentive Plan
Positive
Mar 27, 2026
Covalon Technologies has granted 97,674 deferred share units to four non-employee directors who chose to receive all or part of their fiscal 2026 board fees in equity rather than cash. The awards, issued under the firm’s recently updated lon...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.